Nadofaragene firadenovec

N/A

Report date: 2026/05/09 20:00:18

Base Information

Drug NameNadofaragene firadenovec
Drug Alias NamerAd-IFN/Syn3Ad.hIFN-alpha2brAd-IFNrAd-IFN-2bnadofaragene firadenovec-vncg +[15] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector > Ad5 vector
Mechanisms of ActionGene transferenceInterferon alpha-2 stimulants
TargetsInterferon alpha-2
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsPancreatic Neoplasms +[6] 
Global Approved IndicationsUrinary Bladder Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2022/12/16
Country/TerritoryCzechiaCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesFkd TherapiesSchering-Plough Labo Nv
China Registration ClassN/A

Develop Information

Active CompaniesFerring Ventures LtdSK pharmteco IncThe University Of California Davis +[6] 
Inactive CompaniesFkd Therapies OyNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsPancreatic Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A